Sanofi Upgrades 2024 Business EPS Guidance, Now Expects It To Be Stable At CER From A Prior Forecast Of A Slight Decrease, With A Currency Impact Of -5.5% To -6.5%

7/25/24 1:43:52 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $SNY alert in real time by email

2024 business EPS guidance upgraded • 2024 business EPS(1) to be stable at CER(2), an upgrade from a low single-digit percentage decrease previously, underpinned by accelerated delivery of Sanofi’s pipeline-driven transformation. Applying the average July 2024 exchange rates, the currency impact on 2024 business EPS is c.-5.5% to -6.5%.

Get the next $SNY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SNY

Date	Price Target	Rating	Analyst
7/26/2024	$55.00 → $60.00	Buy	Argus
1/23/2024	$55.00	Equal-Weight	Morgan Stanley
1/16/2024		Buy	UBS
12/5/2023		Overweight → Neutral	JP Morgan
10/30/2023		Buy → Hold	Stifel
9/6/2023		Hold → Buy	Berenberg
7/14/2023		Buy	HSBC Securities
4/28/2023		Hold → Sell	Deutsche Bank

More analyst ratings

$SNY
Market Insights

Live Market Insights

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
On Thursday, Sanofi SA (NASDAQ:SNY) reported a second-quarter business operating income of 2.8 billion euros ($3.03 billion), up 3.2% year-over-year and 8.3% in constant currency. The company reported second-quarter sales of $11.57 billion (10.75 billion euros), beating the consensus of $11.37 billion. Sales increased 7.8% year over year and 10.2% on constant currency. Also Read: Europe Approves Sanofi/Regeneron’s Dupixent for ‘Smoker’s Lungs’ A Month After US FDA Asks For Data. The French drugmaker reported adjusted EPS of $0.93 (1.73 euros), beating the consensus estimate of $0.86, down 0.6% reported and up 4.0% at CER. Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose
7/25/24 8:20:12 AM ET
$AZN
$REGN
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Sanofi shares are trading higher following a Q2 earnings beat.
7/25/24 8:17:08 AM ET
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech space could once again drag the broader market after a few disappointing earnings reports from the likes of Franco-Italian chipmaker STMicroelectronics N.V. (NYSE:STM), which predominantly supplies to the automotive end market, and semiconductor test-equipment company Teradyne, Inc. (NASDAQ:TER). Traders may also stay glued to second-quarter GDP data to confirm the slowdown suggested by some recent data does not point to a hard landing. That said, bond yields are dipping as the market, factori
7/25/24 7:23:10 AM ET
$AAL
$ABBV
$AZN
$BJRI
Air Freight/Delivery Services
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care

Beyfortus® immunization to protect infants from RSV has begun
Six out of 10 infants and newborns in Canada will have access to the protective antibody Beyfortus® for the first time this seasonAccess to Beyfortus® includes infants in remote communities most impacted by respiratory syncytial virus (RSV), in all three territories and northern Quebec and OntarioBeyfortus® demonstrated the ability to reduce the risk of RSV lower respiratory tract infections by 74.5%, including hospitalizations in infants entering their first RSV seasoniTORONTO, Oct. 28, 2024 /CNW/ - Sanofi is pleased to announce Beyfortus® (nirsevimab) will be broadly available for babies born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon this fall. The administration of
10/28/24 5:54:00 PM ET
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals
US FLUBLOK label1 updated to incorporate new safety study in pregnant individualsNew safety data involving more than 48,000 pregnant individuals published in American Journal of Obstetrics and Gynecology (AJOG) Global ReportsRecombinant or inactivated flu vaccines are recommended by the U.S. Centers for Disease Control and Protection (CDC), Advisory Committee on Immunization Practices (ACIP) and American College of Obstetricians and Gynecologists (ACOG) for individuals who are or will become pregnant during flu season2,3,4Sanofi is committed to the ongoing rigorous scientific study of flu vaccines in at-risk populations, including older patients, patients with comorbidities and pregnant indi
10/16/24 12:26:00 PM ET
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies
BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity in clinical studies. The investment over 10 years is aimed at strengthening Centers of Excellence in clinical study diversity at Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine. Funding will be used to hire clinical research staff, establish infrastructure such as online chat services and pharmacy upgrades, create customized training programs, and more. Each of the Centers of Excellence have their own specific needs, which will help them harness t
10/16/24 6:00:00 AM ET
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, toda
5/13/24 7:00:00 AM ET
$FULC
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webcast scheduled for 8:00 a.m. ET today to discuss the collaboration and other recent corporate developments, in conjunction with the first quarter 2024 financial results ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a c
5/13/24 6:00:00 AM ET
$FULC
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a potential multi-billion dollar revenue opportunity for Novavax including:$500 million upfront payment Approximately $70 million equity investment in NovavaxUp to $700 million in COVID-19 and combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to P
5/10/24 2:15:00 AM ET
$NVAX
$SNY
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

$SNY
Leadership Updates

Live Leadership Updates

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer
ROCKVILLE, Md., June 6, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical
6/6/24 7:00:00 AM ET
$AZN
$IMAB
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Sanofi Bridging the Gap between the Homeless and Society via Futsal
Sanofi hosted the founding ceremony of the homeless futsal club ‘Dream' and organized a friendly match as a part of the Helping Hands program Sanofi employees and ‘Dream' members interacted through the friendly match Sanofi has carried out social responsibility activities targeting the homeless and housing vulnerable groups since 2011 Sanofi in Korea[1], the Korean subsidiaries of the global healthcare company Sanofi, hosted the founding ceremony of the homeless futsal club ‘Dream' together with Dalpengyee, a nonprofit organization, to promote self-sufficiency among the homeless. At the founding ceremony of the ‘Dream', held in Seongsu-dong, Seoul on the 17th, the club's first game
10/17/23 9:00:00 AM ET
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care
Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare
BRIDGEWATER, N.J., Aug. 3, 2022 /PRNewswire/ -- Sanofi announces three appointments to key leadership roles for U.S. General Medicines and its North American Vaccines and Consumer Healthcare businesses. Olivier Bogillot becomes Head of U.S. General Medicines. Bogillot, most recently President of Sanofi France, will lead the business unit responsible for serving the Diabetes, Cardiovascular and Transplant communities effective September 1. Bogillot joined Sanofi in 2015, and has held various positions within the company, including as Executive Director of Global Policy based in the U.S. and Chief of Staff to the CEO. In March 2020, he was appointed President of Sanofi France, where he has led
8/3/22 2:53:00 PM ET
$SNY
Biotechnology: Pharmaceutical Preparations
Health Care

Sanofi Upgrades 2024 Business EPS Guidance, Now Expects It To Be Stable At CER From A Prior Forecast Of A Slight Decrease, With A Currency Impact Of -5.5% To -6.5%

Chat with this insight

Recent Analyst Ratings for $SNY

$SNY SEC Filings

SEC Form 6-K filed by Sanofi

SEC Form 6-K filed by Sanofi

SEC Form 6-K filed by Sanofi

$SNY FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

FDA Approval for ADLYXIN issued to SANOFI-AVENTIS US

FDA Approval for SARCLISA issued to SANOFI AVENTIS US

$SNY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Sanofi converted options into 3,088,502 units of Common Stock and bought $1,000,005 worth of Common Stock (66,667 units at $15.00)

SEC Form 3 filed by Sanofi

$SNY Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Sanofi

SEC Form SC 13G filed by Sanofi

SEC Form SC 13G/A filed by Sanofi (Amendment)

$SNY Market Insights

Live Market Insights

Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand

Sanofi shares are trading higher following a Q2 earnings beat.

Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House

$SNY Press Releases

Fastest customizable press release news feed in the world

$SNY Financials

Live finance-specific insights

$SNY Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Beyfortus® immunization to protect infants from RSV has begun

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

Novavax Reports First Quarter 2024 Financial Results and Operational Highlights

Argus reiterated coverage on Sanofi with a new price target

Morgan Stanley initiated coverage on Sanofi with a new price target

UBS resumed coverage on Sanofi

$SNY Leadership Updates

Live Leadership Updates

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

Sanofi Bridging the Gap between the Homeless and Society via Futsal

Sanofi appoints new Heads of U.S. General Medicines, and North America Vaccines and Consumer Healthcare

Recent Analyst Ratings for
$SNY

$SNY
SEC Filings

$SNY
FDA approvals

$SNY
Insider Trading

$SNY
Large Ownership Changes

$SNY
Market Insights

$SNY
Press Releases

$SNY
Financials

$SNY
Analyst Ratings

$SNY
Leadership Updates